Compare KPLT & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPLT | PMN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Canada |
| Employees | 94 | N/A |
| Industry | Diversified Commercial Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 34.6M |
| IPO Year | N/A | 2022 |
| Metric | KPLT | PMN |
|---|---|---|
| Price | $6.94 | $12.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $42.67 |
| AVG Volume (30 Days) | 22.4K | ★ 40.5K |
| Earning Date | 03-11-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.62 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $0.29 |
| 52 Week High | $24.15 | $27.40 |
| Indicator | KPLT | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 33.55 |
| Support Level | $5.78 | $0.41 |
| Resistance Level | $7.58 | $19.85 |
| Average True Range (ATR) | 0.40 | 2.24 |
| MACD | 0.03 | -0.99 |
| Stochastic Oscillator | 73.48 | 5.07 |
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.